These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 31766881)

  • 21. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic
    Tahara M; Kiyota N; Imai H; Takahashi S; Nishiyama A; Tamura S; Shimizu Y; Kadowaki S; Ito KI; Toyoshima M; Hirashima Y; Ueno S; Sugitani I
    Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
    [No Abstract]   [Full Text] [Related]  

  • 22. Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.
    Bueno F; Abelleira E; von Stecher F; de Lima AP; Pitoia F
    Arch Endocrinol Metab; 2021 Nov; 65(2):242-247. PubMed ID: 33587835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
    Kimura T; Doolittle WKL; Kruhlak M; Zhao L; Hwang E; Zhu X; Tang B; Wolcott KM; Cheng SY
    Thyroid; 2024 Apr; 34(4):484-495. PubMed ID: 38115586
    [No Abstract]   [Full Text] [Related]  

  • 24.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
    Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
    Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laryngotracheal Resection After B-Raf Proto-oncogene Inhibition for Anaplastic Thyroid Carcinoma.
    Kent J; Erwin P; Haraf D; Liao CY; Durham J; Angelos P; Agrawal N; Baird BJ; Madariaga MLL
    Ann Thorac Surg; 2023 May; 115(5):e117-e120. PubMed ID: 35504360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation based approaches to the treatment of anaplastic thyroid cancer.
    McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D
    Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
    Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
    Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [No Abstract]   [Full Text] [Related]  

  • 31. Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAF
    Martín-Soberón MC; Ruiz S; De Velasco G; Yarza R; Carretero A; Castellano D; Sepúlveda-Sánchez JM
    J Med Case Rep; 2021 Mar; 15(1):109. PubMed ID: 33653337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
    Califano I; Smulever A; Jerkovich F; Pitoia F
    Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
    Priantti JN; Rodrigues NMV; de Moraes FCA; da Costa AG; Jezini DL; Heckmann MIO
    Endocrine; 2024 Oct; 86(1):284-292. PubMed ID: 38709445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant treatment with lenvatinib and pembrolizumab in a
    Barbaro D; Forleo R; Profilo MA; Lapi P; Giani C; Torregrossa L; Macerola E; Materazzi G
    Front Endocrinol (Lausanne); 2024; 15():1389294. PubMed ID: 39045273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma.
    Yang S; Ji D; Xue F; Chen T; Wang Y; Ji Q
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1770. PubMed ID: 36535914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.
    Hamidi S; Dadu R; Zafereo ME; Ferrarotto R; Wang JR; Maniakas A; Gunn GB; Lee A; Spiotto MT; Iyer PC; Sousa LG; Akhave NS; Ahmed S; Learned KO; Lu C; Lai SY; Williams M; Hosseini SM; Busaidy NL; Cabanillas ME
    JAMA Oncol; 2024 Sep; 10(9):1264-1271. PubMed ID: 38990526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer].
    Altena R; Nilsson M; Bergman V; Dahlberg J; Christofer Juhlin C; Zedenius J
    Lakartidningen; 2024 Feb; 121():. PubMed ID: 38712675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re: "Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
    Smulever A; Barrio Lower Daniele S; Damiano G; Pitoia F
    Thyroid; 2020 Aug; 30(8):1224-1225. PubMed ID: 32397830
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical efficacy with dabrafenib and trametinib in a T599_V600insT poorly differentiated metastatic thyroid carcinoma.
    Lee CS; Miao E; Das K; Seetharamu N
    BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34413035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.